Molecular Partners AG (MOLN)

Business: Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins.

IPO Date: 16-Jun-2021

Co-Founder, CEO, Member of Management Board & Director: Dr. Patrick Amstutz Ph.D.

Co-Founder, COO & Member of Management Board: Dr. Michael Tobias Stumpp Ph.D.

Listing: NASDAQ: MOLN

Country: Switzerland

Headquarters: Schlieren,

Website: https://www.molecularpartners.com

Market cap: $286.03 Mln

Revenue (TTM): CHF180.90 Mln

Earnings (TTM): CHF105.90 Mln

Cash: CHF296.25 Mln

Total Debt: CHF5.74 Mln

Insider's Holding: 0.00%

Liquidity: Low

52 Week range: $5.92 - 32.04

Shares outstanding: 32,325,700

9 Years Aggregate:

• CFO: CHF-237.45 Mln
• EBITDA: CHF-224.39 Mln
• Net Profit: CHF-239.21 Mln